

Further Reading

Suggested by Professor Light

Donald W. Light & Joel Lexchin, *Foreign Free Riders and the High Price of US Medicines*, *BMJ* 2005;331:95, <http://dx.doi.org/10.1136/bmj.331.7522.958>

Joel Lexchin, *Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?*, *BMC Health Services Research* 2011 11:64., <http://www.biomedcentral.com/1472-6963/11/64>.

Donald W. Light & Joel Lexchin, *Pharmaceutical research and development: what do we get for all that money?*, *BMJ* 2012;344:e4348, <http://dx.doi.org/10.1136/bmj.e4348>.

Donald W. Light, *Bearing the Risks of Prescription Drugs*, in *The Risks of Prescription Drugs* (D. Light, ed.), Columbia University Press (2010).

Suggested by Don Cameron

Donald M. Cameron & Kim D. Pressnail, *Judging Science* (paper presented to the National Judicial Institute Science Seminar for the Federal Court and Federal Court of Appeal in 2004), <http://www.jurisdiction.com/judgingscience.pdf>.

Suggested by Dr. Grootendorst

Paul Grootendorst et al., *New approaches to rewarding pharmaceutical innovation*, *Canadian Medical Association Journal* (2011); 183:681-685, <http://www.cmaj.ca/content/183/6/681>

Suggested by Benjamin Gray

Grootendorst & Hollis, *The Canada-European Union Comprehensive Economic & Trade Agreement: An Economic Impact Assessment of Proposed Pharmaceutical Intellectual Property Provisions* (study commissioned by the Canadian Generic Pharmaceutical Association, February 7, 2011), <http://www.canadiangenerics.ca/en/news/docs/02.07.11CETAEEconomicImpactAssessment-FinalEnglish.pdf>